ClinicalTrials.gg
Enrolling by invitationNCT06967649Dental ImplantUpdated May 13, 2025

Prospective Longitudinal Clinical Study for the Evaluation of Peri-implant Tissue and Osseointegration After Rehabilitation With Osseointegrated Implants

An interventional study of TITANIUM IMPLANT in Osseointegration Failure of Dental Implant, Periimplantitis and Peri-Implant Tissues, sponsored by Universidade Federal Fluminense. Enrolling by invitation at 1 site in Brazil. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-05-13.

Sponsored by Universidade Federal Fluminense · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Registered 2 years 5 months after the study started (first participant enrolled Nov 2022, registered May 2025).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
350
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 11 studies in Peri-Implantitis with a site in Brazil — 1 open to participants now, 3 under way, none of them phase 3. Peri-Implantitis · Brazil.

Started
2022
the only one that year
No phase
7 of 11
1 open now
Registered
9th of 11
by date
Lead sponsor
1 of 11
Universidade Federal Fluminense

Among the 11 studies in Peri-Implantitis with a site in Brazil, this one is the only one that started in 2022, is one of 7 with no phase, and was the 9th registered.

Peri-Implantitis

324 studies on the registry are indexed under Peri-Implantitis; 89 are open to participants now.

Browse Peri-Implantitis studies →

Open to participants now

1 of the 11 studies in Peri-Implantitis with a site in Brazil is open now.

A study can be open while its sites in Brazil have not opened yet or have stopped. Only those recruiting at a site in Brazil →

Who these studies take

Of the 50 Peri-Implantitis studies recruiting now, 28 (56%) set no upper age limit and 9 (18%) stop at 75 or younger; 7 take children under 18; 26 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 11 studies in Peri-Implantitis with a site in Brazil, or all of them as a file.
02

Study summary

The success of rehabilitation with osseointegrated implants is associated with numerous factors, including patient characteristics, installed implants, proper planning, and the prosthetic connections used. In the long term, success is closely related to the clinical radiographic follow-up of the implanted region and the identification of intrinsic or extrinsic factors that may interfere with implant survival. Therefore, the objective of this study is to evaluate, through clinical and radiographic analysis, the peri-implant tissues and prosthetic connections of research participants rehabilitated with osseointegrated implants at the Implant Dentistry Clinic of the Federal Fluminense University, over a period of 5 years. This will be a double-blind longitudinal study. A total of 148 research participants will be selected, respecting the inclusion criteria: completion of surgical-prosthetic planning by the Implant Dentistry Clinic team at UFF, including osseointegrated implants and prosthetic components manufactured by SIN Implant System (São Paulo, Brazil); agreeing to and signing the informed consent form, being willing to be monitored for a period of 5 years; systemically healthy patients who do not use antiresorptive and antiangiogenic drugs; patients with a plaque index \<20% (Ainamo \& Bay 1975) and bleeding on probing \<20% (Muhlemann \& Son 1971) at the start of the study. Participants will undergo clinical and radiographic analysis of peri-implant tissues and prosthetic connections at the following intervals: up to 7 days after implant installation (Time 0), at the time of prosthesis installation (Time 1), 6 months after prosthesis installation (Time 2), and 1 to 5 years after prosthesis installation (Times 3, 4, 5, 6, and 7, respectively). It is expected that this longitudinal study will lead to a better understanding of the factors influencing peri-implant bone loss and long-term success.

Read the detailed description

Selection of Research Participants Patients treated in the Implant Dentistry specialization course at FO-UFF, who undergo implant dentistry planning and receive rehabilitative treatment with endosseous implants, will be invited to participate in the research, provided they meet the inclusion criteria.

  • Inclusion Criteria: Completion of surgical-prosthetic planning by the Implant Dentistry Clinic team at UFF, including osseointegrated implants and prosthetic components manufactured by SIN Implant System (São Paulo, Brazil); agreement to sign the informed consent form and willingness to be monitored for a period of 5 years, following the previously established course clinic protocol; systemically healthy patients who do not use antiresorptive and antiangiogenic drugs; patients with a plaque index \<20% (Ainamo \& Bay 1975) and bleeding on probing \<20% (Muhlemann \& Son 1971) at the start of the study.
  • Exclusion Criteria: Patients undergoing rehabilitation with implants from different systems and/or not performed at the UFF Implant Dentistry specialization clinic; patients unable to attend radiographic follow-up over 5 years; patients unable to respond to questions in clinical analysis and satisfaction survey forms; presence of systemic conditions preventing the surgical procedure for dental implant installation; presence of metabolic bone disorders; presence of untreated or uncontrolled chronic or aggressive periodontitis; pregnant or lactating women.

Based on these criteria, a total of 148 research participants will be included and followed for 72 months (6 years).

Installation of Osseointegrated Implants Research participants will undergo clinical and prosthetic planning (reverse planning), including clinical-tomographic examinations and complementary tests, such as biochemical blood analysis and, when necessary, surgical risk assessment, according to the UFF Implant Dentistry specialization course protocol. The surgical technique, type of implant installed, and selected prosthetic components will follow the manufacturer's recommendations (SIN Implant System, São Paulo, Brazil), always considering treatment options for optimal patient rehabilitation.

1.1. Clinical Evaluation The clinical evaluation will include detailed anamnesis, assessment of participant satisfaction, peri-implant clinical examination, and evaluation of prosthetic connections over 5 years (Appendix 2). Clinical data will be updated throughout the study evaluations (Table 1) to analyze possible changes in satisfaction or peri-implant tissue condition.

Immediately after implant installation, primary stability will be assessed, with implants considered stable if inserted with a torque above 30 N/cm, without any mobility (Atsumi et al., 2007).

The peri-implant clinical examination will be performed on the mesial, distal, buccal, and lingual surfaces of each implant using a North Carolina periodontal probe (PCPUNC15-6) Hufriedy do Brasil. The following clinical parameters will be observed: spontaneous bleeding, mobility presence; plaque and calculus presence; keratinized tissue presence; peri-implant biotype; mucosal color changes; presence of swollen areas; implant thread exposure; percussion sensitivity; implant function duration; peri-implant probing depth; bleeding on probing and/or suppuration after gentle probing; percussion sound; bone loss presence beyond what is observed after bone remodeling, as well as anamnesis for health data collection (Appendix 2).

Implants will be considered successful if they have no clinical mobility, absence of clinical symptoms such as swelling, paresthesia, or pain, no damage to surrounding structures, no damage to implant or components, no peri-implant radiolucency, and minimal crest bone height loss, according to Albrektsson et al. (1994) and Misch et al. (2008).

1.2. Radiographic Evaluation The radiographic examination consists of digital periapical radiography using the Shick Elite Digital Indicator Cone radiographic positioner - Indusbello. The choice of this radiographic technique is based on literature data highlighting its advantages, such as reduced magnification and distortion, better resolution, and image detail. All radiographic images will be taken using the same X-ray machine by a single operator, different from the operator conducting the clinical analyses. During the radiographic imaging, participants will wear a lead apron and thyroid collar, in compliance with Federal Ordinance 453/98 (01/06/1998).

The radiographic examination will be performed on all research participants, along with clinical exams at the intervals described in Table 1.

Examiner Calibration:

For the radiographic evaluations, a dentist will be calibrated to measure the distance from the implant platform to the first point of contact between bone and implant on the mesial and distal surfaces, using tools such as zoom and digital measurement in a specific image software (ImageProPlus® - Media Cybernetics, Inc.401 N. Washington Street, Suite 350 - Rockville, MD 20850 - United States). After 24 hours, the measurements will be repeated to verify the consistency of results and obtain calibration correlation.

The radiographs will be digitized and evaluated using the image software (ImageProPlus®) for the following parameter: Height of the Marginal Peri-implant Bone Crest: linear measurement of the distance from the implant platform to the first point of contact between bone and implant on the mesial and distal surfaces.

Physiological bone loss will be characterized by considering normal bone loss of one millimeter during the first year after implant placement and 0.2 mm per subsequent year, in accordance with the osseointegration period. Thus, the total amount of bone loss will be calculated based on diagnostic radiography, compared to the clinical implant placement protocol. If total bone loss exceeds 1 mm and 0.2 mm per year, the region will be diagnosed with peri-implantitis (Roos et al., 1997).

1.3. Tomographic Evaluation The tomographic examination will be conducted in partnership with a radiology clinic to be defined, using cone beam computed tomography (CBCT).

According to Monje et al. 2019, measurement accuracy is influenced by defect size and image quality. Intraoral radiography provides a two-dimensional image of the peri-implant bone, describing mesial and distal bone sites; however, it may underestimate incipient lesions and intraosseous defects. Geometric distortions and anatomical overlaps may also occur. In cases where three-dimensional bone visualization is necessary, CBCT can be the alternative.

Participants diagnosed with pathological bone loss radiographically will undergo a tomographic examination at the peri-implant diseased site, aiming to obtain a three-dimensional anatomical image of the bone with its peri-implant defect, serving as a comparison and analysis for the treatment option to be offered.

1.4. Statistical Analysis Prisma GraphPad 6.0 software (GraphPad Software, La Jolla, CA, USA) will be used for all statistical analyses. The distribution type of numerical variables, including clinical data and radiographic measurements, will be assessed using the Shapiro-Wilk test. Student's t-tests or Mann-Whitney tests will be applied for normally or non-normally distributed data, respectively. Paired analyses will be conducted for characteristic comparisons with a significance level of 0.05% (p\<0.05). Logistic regression will evaluate the correlation of analyzed factors over the years and the success of rehabilitation.

03

Conditions studied

  • Osseointegration Failure of Dental Implant
  • Periimplantitis
  • Peri-Implant Tissues
  • Peri-Implant Health
  • Peri-implant Soft Tissue Healing
  • Implant Survival Using Immediate Loading Protocol
  • Dental Implant Stability
  • Prospective Study
  • Osseointegration

Browse trials for

Keywords

  • PERI-IMPLANT HEALTH
  • Dental implant survival rate
  • DENTAL IMPLANT
  • prospective study
  • osseointegration
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria: Completion of surgical-prosthetic planning by the Implant Dentistry Clinic team at UFF, including osseointegrated implants and prosthetic components manufactured by SIN Implant System (São Paulo, Brazil); agreement to sign the form and willingness to be monitored for a period of 5 years, following the previously established course clinic protocol; systemically healthy patients who do not use antiresorptive and antiangiogenic drugs; patients with a plaque index \<20% (Ainamo \& Bay 1975) and bleeding on probing \<20% (Muhlemann \& Son 1971) at the start of the study.

-

Exclusion Criteria: Patients undergoing rehabilitation with implants from different systems and/or not performed at the UFF Implant Dentistry specialization clinic; patients unable to attend radiographic follow-up over 5 years; patients unable to respond to questions in clinical analysis and satisfaction survey forms; presence of systemic conditions preventing the surgical procedure for dental implant installation; presence of metabolic bone disorders; presence of untreated or uncontrolled chronic or aggressive periodontitis; pregnant or lactating women.

-

Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
350 participants (estimated)

Study arms

  • Active comparator
    IMPLANT PLACEMENT

    Research participants will undergo clinical and prosthetic planning (reverse planning), including clinical-tomographic examinations and complementary tests, such as biochemical blood analysis and, when necessary, surgical risk assessment, according to the UFF Implant Dentistry specialization course protocol. The surgical technique, type of implant installed, and selected prosthetic components will follow the manufacturer's recommendations (SIN Implant System, São Paulo, Brazil), always considering treatment options for optimal patient rehabilitation.

    Device: TITANIUM IMPLANT

Interventions

  • DeviceTITANIUM IMPLANT

    The surgical technique, type of implant installed, and selected prosthetic components will follow the manufacturer's recommendations (SIN Implant System, São Paulo, Brazil), always considering treatment options for optimal patient rehabilitation.

06

What researchers measure

Primary outcomes

  1. PRIMARY IMPLANT STABILITY

    Data on the clinical and radiographic characteristics of the different installed implants and the short-term stability of their prosthetic connections will be obtained. Over the years of evaluation, there may be better recognition of the factors influencing peri-implant bone loss and long-term success.

    Time frame: From enrollment to the end of treatment at 6 months

07

Study locations

1 site
  • Universidade Federal Fluminense
    Niteroi, RJ 24020140, Brazil
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2022 to primary completion in Oct 2023, 11 months.

Of 121 non-industry interventional studies with no phase under Peri-Implantitis, half reached primary completion within 26 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 46. This study's 11 months is below that.

Counting every sponsor, half of 128 studies reached it within 26 months; a quarter within 12 and three quarters within 40.

How these figures are worked out, and which studies are left out of them.

Registered
May 3, 2025
First posted
May 13, 2025
StartActual
Nov 4, 2022
Primary completionActual
Oct 4, 2023
CompletionEst.
Feb 2028
Last update
May 13, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 13, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06967649
Lead sponsor
Universidade Federal Fluminense
Responsible party
Priscila Ladeira Casado (PhD in Morphology , Professor and Researcher at the Universidade Federal Fluminense, Universidade Federal Fluminense) — Principal investigator
First posted
May 13, 2025
Start date
Nov 4, 2022
Primary completion
Oct 4, 2023
Completion
Feb 2028 (estimated)
Last update
May 13, 2025

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion